Our hypothesis is that administration of intact protein into the duodenum will be more satiating compared to oral administration.
ID
Bron
Verkorte titel
Aandoening
Obesity, dietary proteins, oral administration, duodenal administration, satiety
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The effects of orally- and intraduodenally administered intact protein on systemic satiety hormone levels (CCK, GLP-1, and PYY) and feelings of hunger and satiety
Achtergrond van het onderzoek
This study will investigate the effects of different administration routes of pea protein on intestinal satiety hormone release, on plasma satiety hormone levels and on feelings of hunger and satiety.
This study is a randomized, placebo controlled cross-over study with 2 groups of volunteers. One group will consist of healthy lean male subjects. The other group will consist of obese male subjects.
All subjects will receive both pea protein and placebo, administered either orally or intraduodenally, depending on the test day.
All subjects will visit the university on four occasions. On these test days, subjects will receive placebo or pea protein, either orally or intraduodenally. Two consecutive test sessions will be interspaced with a one-week washout period. Blood samples will be collected during a 2h period, and a questionaire will be filled in by the subjects. Levels of CCK and GLP-1 will be measured in the bloodsamples.
Doel van het onderzoek
Our hypothesis is that administration of intact protein into the duodenum will be more satiating compared to oral administration.
Onderzoeksopzet
All subjects will visit the university on four occasions. On these test days, subjects will receive placebo or pea protein, either orally or intraduodenally. Two consecutive test sessions will be interspaced with a one-week washout period.
Onderzoeksproduct en/of interventie
This study is a randomized, placebo controlled cross-over study with 2 groups of volunteers. One group will consist of healthy lean male subjects. The other group will consist of obese male subjects.
All subjects will receive both the test protein and the placebo, administered either orally or intraduodenally, depending on the test day. Delievery of the protein and placebo into the duodenum will be through a feeding tube.
- Oral ingestion placebo
- Oral ingestion protein
- Duodenal administration placebo
- Duodenal administration protein
All conditions are randomized over 4 test days
- Gastroscopy on the 5h test day
Algemeen / deelnemers
PO Box 616
M.C.P. Geraedts
Maastricht 6200 MD
The Netherlands
+31 (0)43 3884259
M.Geraedts@HB.unimaas.nl
Wetenschappers
PO Box 616
M.C.P. Geraedts
Maastricht 6200 MD
The Netherlands
+31 (0)43 3884259
M.Geraedts@HB.unimaas.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Male, non smoking
2. Age between 18 and 65 years
3. Body Mass Index for lean subjects between 20 and 26 kg/m2
4. Body Mass Index for obese subjects between 30 and 37 kg/m2
5. No medication
6. No history of intestinal illness
7. Stable body weight over the last three months
8. No blood donation 2 months prior to the study and during the study
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Age under 18 and over 65 years
2. BMI under 20 and over 37 kg/m2
3. Medication or disease that could interfere with the results of the study, to be judged by the responsible medical doctor
4. Recent blood donation within 2 months prior to the start of the study
5. Intestinal illness at any time in the past
6. Female
7. Smokers
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1376 |
| NTR-old | NTR1437 |
| Ander register | : MEC08-3-058 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |